Seraxis gathers $40m Series C

Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing.

Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing. Eli Lilly and Company led the round with participation from other investors that included Frazier Healthcare Partners, Polaris Ventures and JDRF T1D Fund.

Source: Press Release